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A commentary on
Case records of the Massachusetts General 
Hospital. Case 6-2012. A 45-year-old man 
with a history of alcohol abuse and rapid 
cognitive decline
by Cho, T. A., Larvie, M., Tian, D., and 
 Mino-Kenudson, M. (2012). N. Engl. J. Med. 
366, 745–755.
In a recent issue of the New England 
Journal of Medicine, Cho et al. (2012) 
provided an interesting and very com-
prehensive description of an alcohol-
dependent patient affected by alcoholic 
liver disease with fibrosis, brain abscess due 
to toxoplasma, and advanced HIV infec-
tion. This case report is a good reminder 
of three important clinical issues, i.e. (a) 
HIV-infected alcoholic patients drink 
more than the general population, alco-
hol is their most commonly abused drug 
and contributes to HIV-related morbidity, 
mortality, and transmission (Fenton et al., 
2010); (b) HIV-infected alcoholic patients 
often have hepatic impairment because of 
alcohol’s effects on liver, HCV coinfection, 
and antiretroviral therapy (ART)-related 
hepatotoxicity risk (Szabo and Zakhari, 
2011); indeed, alcohol alone, like in this 
patient (Cho et al., 2012), can be harm-
ful enough to develop clinically significant 
ALD – notably, in this patient ALD delayed 
ART initiation (Cho et al., 2012), which 
may have contributed to further clinical 
deterioration; (c) Alcohol interventions 
are dramatically needed for HIV-infected 
patients. This patient had declined treat-
ment, e.g., disulfiram (Cho et al., 2012), 
a drug that itself might cause liver failure 
(Edwards et al., 2011). Though prelimi-
nary research is searching for safer and 
more effective pharmacotherapies (e.g., 
Addolorato et al., 2007; Johnson et al., 
2008; Leggio et al., 2011, 2012), this case 
(Cho et al., 2012) highlights the need to 
identify novel pharmacotherapies for alco-
holic patients with ALD in order to provide 
effective interventions that both promote 
abstinence and help prevent progression to 
hepatic failure and death.
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